NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 1,781 shares of the business's stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $14.06, for a total value of $25,040.86. Following the completion of the transaction, the insider now owns 3,435,541 shares in the company, valued at approximately $48,303,706.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Monday, April 22nd, Orbimed Advisors Llc sold 24,609 shares of NeuroPace stock. The shares were sold at an average price of $14.05, for a total value of $345,756.45.
- On Thursday, April 18th, Orbimed Advisors Llc sold 2,623 shares of NeuroPace stock. The shares were sold at an average price of $14.06, for a total value of $36,879.38.
- On Tuesday, April 16th, Orbimed Advisors Llc sold 14,069 shares of NeuroPace stock. The shares were sold at an average price of $14.01, for a total value of $197,106.69.
- On Thursday, April 11th, Orbimed Advisors Llc sold 461,899 shares of NeuroPace stock. The shares were sold at an average price of $14.49, for a total value of $6,692,916.51.
NeuroPace Trading Up 3.1 %
NPCE opened at $13.39 on Friday. NeuroPace, Inc. has a 1-year low of $3.80 and a 1-year high of $18.15. The company has a debt-to-equity ratio of 2.76, a quick ratio of 5.02 and a current ratio of 5.71. The stock's 50 day simple moving average is $14.25 and its 200 day simple moving average is $11.59.
1970’s computer coder Issues Shocking AI Warning
From InvestorPlace | Ad
Louis Navellier has spent four decades building a billion-dollar empire on the back of big data and technology…
Now he's stepping forward with a shocking warning about how AI will soon impact the wealth of everyday Americans.
Click here to watch his new video ASAP
NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.10. NeuroPace had a negative return on equity of 153.76% and a negative net margin of 50.38%. The firm had revenue of $18.01 million for the quarter, compared to analyst estimates of $17.74 million. On average, sell-side analysts anticipate that NeuroPace, Inc. will post -1.14 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. Kent Lake Capital LLC lifted its stake in shares of NeuroPace by 16.8% during the 4th quarter. Kent Lake Capital LLC now owns 670,946 shares of the company's stock worth $6,917,000 after purchasing an additional 96,529 shares during the period. Citigroup Inc. purchased a new position in shares of NeuroPace during the 3rd quarter worth $29,000. EAM Investors LLC purchased a new position in shares of NeuroPace during the 3rd quarter worth $1,378,000. Finally, Barclays PLC lifted its stake in shares of NeuroPace by 9,085.6% during the 3rd quarter. Barclays PLC now owns 10,839 shares of the company's stock worth $105,000 after purchasing an additional 10,721 shares during the period. Hedge funds and other institutional investors own 78.83% of the company's stock.
Analyst Ratings Changes
Several research firms have issued reports on NPCE. Cantor Fitzgerald boosted their target price on NeuroPace from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 6th. Wells Fargo & Company upgraded NeuroPace from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $16.00 to $20.00 in a research report on Thursday, March 14th. Leerink Partnrs reiterated an "outperform" rating on shares of NeuroPace in a research report on Tuesday, January 30th. Morgan Stanley boosted their target price on NeuroPace from $9.00 to $13.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 6th. Finally, SVB Leerink began coverage on NeuroPace in a research report on Tuesday, January 30th. They set an "outperform" rating and a $22.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $15.67.
View Our Latest Report on NPCE
NeuroPace Company Profile
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
